Your browser doesn't support javascript.
loading
Neuropathological findings in Down syndrome, Alzheimer's disease and control patients with and without SARS-COV-2: preliminary findings.
Granholm, Ann-Charlotte E; Englund, Elisabet; Gilmore, Anah; Head, Elizabeth; Yong, William H; Perez, Sylvia E; Guzman, Samuel J; Hamlett, Eric D; Mufson, Elliott J.
Afiliação
  • Granholm AE; Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Research Complex II, Aurora, CO, USA. Lotta.granholm@cuanschutz.edu.
  • Englund E; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Gilmore A; Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Research Complex II, Aurora, CO, USA.
  • Head E; Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA, USA.
  • Yong WH; Department of Neurology, University of California Irvine, Irvine, CA, USA.
  • Perez SE; Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA, USA.
  • Guzman SJ; Department of Translational Neuroscience and Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Hamlett ED; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Mufson EJ; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.
Acta Neuropathol ; 147(1): 92, 2024 05 27.
Article em En | MEDLINE | ID: mdl-38801558
ABSTRACT
The SARS-CoV-2 virus that led to COVID-19 is associated with significant and long-lasting neurologic symptoms in many patients, with an increased mortality risk for people with Alzheimer's disease (AD) and/or Down syndrome (DS). However, few studies have evaluated the neuropathological and inflammatory sequelae in postmortem brain tissue obtained from AD and people with DS with severe SARS-CoV-2 infections. We examined tau, beta-amyloid (Aß), inflammatory markers and SARS-CoV-2 nucleoprotein in DS, AD, and healthy non-demented controls with COVID-19 and compared with non-infected brain tissue from each disease group (total n = 24). A nested ANOVA was used to determine regional effects of the COVID-19 infection on arborization of astrocytes (Sholl analysis) and percent-stained area of Iba-1 and TMEM 119. SARS-CoV-2 antibodies labeled neurons and glial cells in the frontal cortex of all subjects with COVID-19, and in the hippocampus of two of the three DS COVID-19 cases. SARS-CoV-2-related alterations were observed in peri-vascular astrocytes and microglial cells in the gray matter of the frontal cortex, hippocampus, and para-hippocampal gyrus. Bright field microscopy revealed scattered intracellular and diffuse extracellular Aß deposits in the hippocampus of controls with confirmed SARS-CoV-2 infections. Overall, the present preliminary findings suggest that SARS-CoV-2 infections induce abnormal inflammatory responses in Down syndrome.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Síndrome de Down / Doença de Alzheimer / COVID-19 Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Síndrome de Down / Doença de Alzheimer / COVID-19 Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article